Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512365 · ClinicalTrials.gov registry record · Early Phase 1
Reward and Drug Effects on Mood and Brain Response
A Early Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 141
- Enrollment target
NCT04512365 is a Early Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 141 participants.
The verdict
NCT04512365, a Early Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
Interventions
- DRUG THC
- DRUG Placebo oral capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2025-05-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04512365
The ClinicalTrials.gov registry entry for NCT04512365 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which THC is the first listed.
NCT04512365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04512365 about?
NCT04512365 is a clinical study titled "Reward and Drug Effects on Mood and Brain Response". The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
What is the current status of trial NCT04512365?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 141 participants. The study started on 2021-03-16. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT04512365?
The interventions under investigation include: THC (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT04512365?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.